GlassScriptPhysician profile
Benjamin R Broome
NPI 1467773671
$2,861.90
in general payments reported to CMS, 2019-2025
19 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $224 · 2021: $147 · 2022: $483 · 2023: $680 · 2024: $404 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $714.83 | 2019-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $419.89 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Vifor Pharma, INC. | $357.34 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $280.06 | 2019-2024 | Soliris |
| Bayer Healthcare Pharmaceuticals INC. | $213.92 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $126.47 | 2020-2024 | Jynarque |
| Akebia Therapeutics INC | $102.87 | 2020-2023 | Auryxia |
| Novo Nordisk INC | $101.26 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Travere Therapeutics, INC. | $88.82 | 2022-2025 | |
| Amgen INC. | $68.22 | 2023-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $67.22 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $58.41 | 2020-2021 | |
| Glaxosmithkline, LLC. | $53.47 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $44.99 | 2022-2024 | Lupkynis |
| Kyowa Kirin, INC. | $44.67 | 2023-2024 | Crysvita |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $37.37 | 2019 | |
| Horizon Therapeutics Plc | $32.53 | 2023 | Krystexxa |
| Abbvie INC. | $31.44 | 2022 | |
| Genzyme Corporation | $18.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Broome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.